Condition: Stroke
Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?
Please use this link to access this publication. Abstract Central pain after stroke due to brainstem infarction is very rare. Treatment is difficult and specific guidelines are lacking. This is…
Cannabidiol Exerts a Neuroprotective and Glia-Balancing Effect in the Subacute Phase of Stroke
Please use this link to access this publication Abstract: Pharmacological agents limiting secondary tissue loss and improving functional out comes after stroke are still limited. Cannabidiol (CBD), the major non-psychoactive…
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Abstract Anecdotal evidence that cannabis preparations have medical benefits together with the discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated efforts to develop cannabinoid-based therapeutics. These efforts have been…
Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke
Cannabis contains the psychoactive component delta9 -tetrahydrocannabinol (delta9 -THC), and the non-psychoactive components cannabidiol (CBD), cannabinol, and cannabigerol. It is well-known that delta9 -THC and other cannabinoid CB1 receptor agonists…
Update on the Role of Cannabinoid Receptors after Ischemic Stroke
Cannabinoids are considered as key mediators in the pathophysiology of inflammatory diseases, including atherosclerosis. In particular, they have been shown to reduce the ischemic injury after acute cardiovascular events, such…